ClinicalTrials.gg
CompletedNCT00012389Updated Dec 19, 2013

Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

A Phase 3 interventional study of irinotecan hydrochloride and oxaliplatin in Colorectal Cancer, sponsored by Sanofi. Completed at 154 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-19.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 200 studies testing irinotecan in Colorectal Neoplasms — 25 open to participants now, 32 under way, 6 of them phase 3. Irinotecan · Colorectal Neoplasms.

Started
2000
with 7 others
Phase 3
26 of 200
3 open now
Registered
20th of 200
by date

Among the 200 studies testing irinotecan in Colorectal Neoplasms, this one is one of 8 that started in 2000, is one of 26 in phase 3, and was the 20th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

25 of the 200 studies testing irinotecan in Colorectal Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies testing irinotecan in Colorectal Neoplasms, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if irinotecan is more effective with or without oxaliplatin in treating metastatic colorectal cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of irinotecan with or without oxaliplatin in treating patients who have metastatic colorectal cancer.

Read the detailed description

OBJECTIVES:

  • Compare the overall survival of patients with metastatic colorectal cancer treated with irinotecan with or without oxaliplatin.
  • Compare the response rate, time to tumor-related worsening of symptoms, time to disease progression, onset and duration of responses, and duration of disease stabilization in these patients treated with these regimens.
  • Compare the safety of these regimens in these patients.

OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified according to Karnofsky performance status (50-60% vs 70-100%), number of metastatic organs involved (1 vs 2 or more), lactic dehydrogenase (no greater than 1.5 times upper limit of normal (ULN) vs greater than 1.5 times ULN), and prior fluorouracil chemotherapy (adjuvant vs first-line treatment for metastatic disease). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive irinotecan IV over 90 minutes on day 1.
  • Arm II: Patients receive oxaliplatin IV over 120 minutes followed by irinotecan IV over 30 minutes on day 1.

Courses repeat in each arm every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity.

Patients are followed at 30 days, every 4 weeks for 3 months, and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 596 patients (298 per arm) will be accrued for this study within 18 months.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • stage IV colon cancer
  • stage IV rectal cancer
  • recurrent colon cancer
  • recurrent rectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • or cytologically confirmed adenocarcinoma of the colon or rectum
  • or recurrent disease that is not amenable to potentially curative treatment
  • Progressive or recurrent disease during or after 1, and only 1, regimen of fluorouracil with or without leucovorin calcium or during or within 6 months after chemotherapy with fluorouracil and leucovorin calcium

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • 50-100%

:

  • Not specified

Hematopoietic:

  • at least 1,500/mm\^3
  • count at least 100,000/mm\^3

Hepatic:

  • no greater than 1.5 times (ULN)
  • /SGPT no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present)
  • Alkaline phosphatase no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present)

Renal:

  • Creatinine no greater than 1.5 times ULN

Cardiovascular:

  • No unstable angina
  • No class III or IV congestive heart failure
  • No serious cardiac arrhythmia
  • No history of cardiac toxicity from fluorouracil/leucovorin calcium
  • No myocardial infarction within past 6 months

Pulmonary:

  • No interstitial pneumonia or extensive and symptomatic fibrosis of the lung

Other:

  • No uncontrolled predisposing colonic or small bowel disorder
  • No prior chronic enteropathy, chronic diarrhea, or unresolved bowel obstruction/subobstruction
  • No diabetes
  • No active infection
  • No known current peripheral neuropathy
  • No concurrent active cancer except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix
  • No intolerance of appropriate antiemetics
  • No history of anaphylaxis or potential intolerance to atropine sulfate or loperamide
  • Not pregnant or nursing
  • Negative pregnancy test

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy
  • No prior irinotecan or oxaliplatin
  • No other prior chemotherapy agents except fluorouracil with or without leucovorin calcium as therapy for metastatic disease or in the adjuvant setting

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Prior radiotherapy to non-target lesions allowed
  • No prior radiotherapy to target lesions unless disease progression is documented within the radiation port
  • At least 3 weeks since prior radiotherapy

Surgery:

  • At least 4 weeks since prior major surgical procedure and recovered
  • Prior surgery for primary tumor or metastasis allowed

Other:

  • At least 30 days since prior drug
  • No concurrent investigational agents
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Masking
None (open label)
06

Study locations

154 sites
  • Comprehensive Cancer Institute of Huntsville
    Huntsville, Alabama 35801, United States
  • Oncology Center at Providence Park
    Mobile, Alabama 36688, United States
  • Arizona Clinical Research Center
    Tucson, Arizona 85712, United States
  • Citrus Valley Medical Center
    Covina, California 91722, United States
  • California Cancer Care, Inc.
    Greenbrae, California 94904-2007, United States
  • Tower Hematology Oncology Medical Group
    Los Angeles, California 90048, United States
  • Kenmar Research Institute
    Los Angeles, California 90057, United States
  • Los Angeles, California 90067, United States
  • Medical Oncology Care Associates
    Orange, California 92868, United States
  • P.M.K. Medical Group, Inc.
    Oxnard, California 93030, United States
  • Cancer and Blood Institute of the Desert
    Rancho Mirage, California 92270, United States
  • Kaiser Permanente-Southern California Permanente Medical Group
    San Diego, California 92120, United States
  • John Wayne Cancer Institute
    Santa Monica, California 90404, United States
  • Kaiser Permanente Medical Center - Vallejo
    Vallejo, California 94589, United States
  • Colorado Permanente Medical Group, P.C.
    Denver, Colorado 80205, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • University of Colorado Cancer Center
    Denver, Colorado 80220, United States
  • Whittingham Cancer Center
    Norwalk, Connecticut 06856, United States
  • George Washington University Medical Center
    Washington, District of Columbia 20037, United States
  • Comprehensive Cancer Care Specialists of Boca Raton
    Boca Raton, Florida 33428, United States
  • Center for Hematology-Oncology
    Boca Raton, Florida 33486, United States
  • Southeast Florida Hematology-Oncology Group
    Fort Lauderdale, Florida 33308, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Shands Hospital and Clinics, University of Florida
    Gainesville, Florida 32610-100277, United States
  • Hematology and Oncology Associates of Jacksonville
    Jacksonville, Florida 32207, United States
  • University of Florida Health Science Center - Jacksonville
    Jacksonville, Florida 32209, United States
  • Lakeland Regional Medical Center
    Lakeland, Florida 33804, United States
  • Lake Heart and Cancer Medical Center
    Leesburg, Florida 34748, United States
  • Oncology-Hematology Group of South Florida
    Miami, Florida 33176, United States
  • Hematology and Oncology Consultants, P.A.
    Orlando, Florida 32804, United States
  • Hematology/Oncology Associates
    Port Saint Lucie, Florida 34952, United States
  • Oncology & Hematology Associates of West Broward
    Tamarac, Florida 33321, United States
  • University Community Hospital
    Tampa, Florida 33613, United States
  • Hematology and Oncology Consultants
    Titusville, Florida 32796, United States
  • North Idaho Cancer Center
    Coeur d'Alene, Idaho 83814, United States
  • Northwest Medical Specialists, P.C.
    Arlington Heights, Illinois 60004, United States
  • Dreyer Medical Clinic
    Aurora, Illinois 60506, United States
  • Northwestern Medical Faculty Foundation
    Chicago, Illinois 60611, United States
  • Cancer Care Center
    New Albany, Indiana 47150, United States
  • Albert B. Chandler Medical Center, University of Kentucky
    Lexington, Kentucky 40536-0084, United States
  • James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Kentuckiana Cancer Institute
    Louisville, Kentucky 40202, United States
  • Norton Healthcare Pavilion
    Louisville, Kentucky 40202, United States
  • Veterans Affairs Medical Center - Louisville
    Louisville, Kentucky 40206, United States
  • Baton Rouge General Medical Center
    Baton Rouge, Louisiana 70806, United States
  • Louisiana Oncology Associates
    Lafayette, Louisiana 70506, United States
  • Doctors Hospital of Jefferson
    Metairie, Louisiana 70006, United States
  • Stanley Scott Cancer Center
    New Orleans, Louisiana 70112, United States
  • Greater Baltimore Medical Center and Cancer Center
    Baltimore, Maryland 21204, United States
  • Medical Center of Boston
    Boston, Massachusetts 02120, United States
  • Berkshire Hematology Oncology, P.C.
    Pittsfield, Massachusetts 01201, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201-1379, United States
  • Flint, Michigan 48532, United States
  • Parker Hughes Cancer Center
    Roseville, Minnesota 55113, United States
  • Jackson Oncology Associates, PLLC
    Jackson, Mississippi 39202, United States
  • Veterans Affairs Medical Center - Kansas City
    Kansas City, Missouri 64128, United States
  • Siteman Cancer Center
    Saint Louis, Missouri 63110, United States
  • St. John's Mercy Medical Center
    Saint Louis, Missouri 63141, United States
  • Missouri Cancer Care, P.C.
    St. Charles, Missouri 63301, United States
  • Great Falls Clinic
    Great Falls, Montana 59405, United States
  • Western Montana Clinic
    Missoula, Montana 59807-7609, United States
  • Somerset Medical Center
    Somerville, New Jersey 08876, United States
  • Cooper Cancer Institute
    Voorhees, New Jersey 08043, United States
  • Veterans Affairs Medical Center - Albany
    Albany, New York 12208, United States
  • Montefiore Medical Center
    Bronx, New York 10467-2490, United States
  • Queens Medical Associates, PC
    Fresh Meadows, New York 11365, United States
  • Queens Hospital Center
    Jamaica, New York 11432, United States
  • Interlakes Oncology/Hematology PC
    Rochester, New York 14623, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Lineberger Comprehensive Cancer Center, UNC
    Chapel Hill, North Carolina 27599-7295, United States
  • Raleigh Hematology/Oncology Associates - Wake Practice
    Raleigh, North Carolina 27609, United States
  • Piedmont Hematology-Oncology Associates
    Winston-Salem, North Carolina 27103, United States
  • Cleveland Clinic Taussig Cancer Center
    Cleveland, Ohio 44195, United States
  • Hematology Oncology Consultants Inc
    Columbus, Ohio 43235, United States
  • Bend Memorial Clinic
    Bend, Oregon 97701, United States
  • Kaiser Permanente - Portland
    Portland, Oregon 97227, United States
  • Pinnacle Health Hospitals
    Harrisburg, Pennsylvania 17105-8700, United States
  • Abington Hematology Oncology Associates, Incorporated
    Meadowbrook, Pennsylvania 18974, United States
  • University of Pennsylvania Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • Pennsylvania Oncology Hematology Associates
    Philadelphia, Pennsylvania 19106, United States
  • University of Pittsburgh Cancer Institute
    Pittsburgh, Pennsylvania 15213, United States
  • Lifespan: The Miriam Hospital
    Providence, Rhode Island 02906, United States
  • Physicians East - Quadrangle
    Greenville, South Carolina 27834, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29615, United States
  • Erlanger Health Systems
    Chattanooga, Tennessee 37403, United States
  • Baptist Regional Cancer Center - Knoxville
    Knoxville, Tennessee 37901, United States
  • West Clinic
    Memphis, Tennessee 38117, United States
  • Memphis Cancer Center
    Memphis, Tennessee 38119, United States
  • Tennessee Oncology, P.L.L.C.
    Nashville, Tennessee 37205, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232-6307, United States
  • Lone Star Oncology
    Austin, Texas 78759, United States
  • Center for Oncology Research and Treatment, Medical City Hospital
    Dallas, Texas 75230, United States
  • Baptist Health System Cancer Program
    San Antonio, Texas 78205, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Cancer Center at the University of Virginia
    Charlottesville, Virginia 22908, United States
  • Hematology-Oncology Associates of Frederiksburg, Inc.
    Fredericksburg, Virginia 22401, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Advanced Health Care
    Milwaukee, Wisconsin 53209, United States
  • UW Cancer Center Wausau Hospital
    Wausau, Wisconsin 54401, United States
  • Irving Cancer Center
    Laramie, Wyoming 82070, United States

Showing the first 100 of 154 sites across 7 countries. Choose a country and city above to see the rest.

07

References and documents

Publications

  • Haller DG, Rothenberg ML, Wong AO, Koralewski PM, Miller WH Jr, Bodoky G, Habboubi N, Garay C, Olivatto LO. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol. 2008 Oct 1;26(28):4544-50. doi: 10.1200/JCO.2008.17.1249. PubMed 18824706 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2000 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2001
First posted
Jan 27, 2003
Start
Dec 2000
CompletionActual
Oct 2008
Last update
Dec 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00012389
Lead sponsor
Sanofi
First posted
Jan 27, 2003
Start date
Dec 2000
Completion
Oct 2008
Last update
Dec 19, 2013

Study contacts

Daniel G. Haller, MD
study chair · Abramson Cancer Center at Penn Medicine
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2002. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan · Oxaliplatin

Start the discussion